Replies to post #108608 on Biotech Values

[iwfal]

VRTX adds ribavirin arm to VX-222/Telaprevir all-oral HCV trial:

This will make for interesting data - but will hold up the completion of the trial substantially (since the Clinical Trial site shows enrollment complete)


From the Press Release:

The planned treatment arm is supported by emerging data from multiple ongoing clinical trials of direct-acting antiviral (DAA) therapies, including the trial of telaprevir/VX-222-based combination therapy, which suggest that adding ribavirin to a DAA treatment regimen may increase antiviral activity.

? I don't remember having seen SVR or ETR data for rib + DAA (wo IFN) from any trial. But perhaps I missed it?